Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a class of drugs for the treatment of multiple diseases and disorders of the central nervous system. The company’s NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. The company has a clinical-stage product pipeline and multiple preclinical product candidates. Its most advanced product candidates are in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer’s disease and cognitive dysfunction in schizophrenia.
Changed name to Catalyst Biosciences, Inc. from Targacept, Inc., 8/23/2023.